a , GLP-1R (WT), b , GLP-1R triple mutant (L142A, K202A, Y145A), c , GLP-1R (K202A), d , GLP-1R (Y145A), e , GLP-1R (Y145F)
Currently, there is no official link established between Ozempic and direct bladder pathology in the product's Summary of Product Characteristics (SmPC) approved by the Medicines and Healthcare products Regulatory Agency (MHRA) or in guidance from the National Institute for Health and Care Excellence (NICE)
So the picture for a lot of folk ends up looking like this
Obviously: these awards are typically reserved for universities
Yesclinical trial results show meaningful, real-world weight loss
Phase 2 retatrutide data suggest ~2428% weight loss at 48 weeks